Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Moderna’s COVID-19 Vaccine Passes First Test In Elderly Patients

Encouraging Results From Phase I Study

Executive Summary

Plus: Korea approves Celltrion antibody trial in mild patients, promising signs for Translate Bio's mRNA candidate in animal studies.

You may also be interested in...



US COVID Vaccine Early Distribution Plans Assume Emergency Use Authorization First

CDC developing vaccine distribution plans with four states and one large city that will serve as a foundation for other jurisdictions; plans include provisions for all potential vaccines, but logistics will vary depending on product, especially given the cold chain issues associated with mRNA vaccines from Pfizer and Moderna.

Coronavirus Update: Moderna Could Have Advantage Over Pfizer’s Cold Chain

Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.

Coronavirus Update: Human Vaccine Challenge Study Gains UK Backing

The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel